Trial · NCT02841995
Results by group881
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 881
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Overall Response (OR) | Cohort 1: Belumosudil 200 mg QD | 64.7 | 95% Confidence Interval 38.3 to 85.8 | percentage of participants | |
| Percentage of Participants With Overall Response (OR) | Cohort 2: Belumosudil 200 mg BID | 68.8 | 95% Confidence Interval 41.3 to 89.0 | percentage of participants | |
| Percentage of Participants With Overall Response (OR) | Cohort 3: Belumosudil 400 mg QD | 57.1 | 95% Confidence Interval 34.0 to 78.2 | percentage of participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 1: Belumosudil 200 mg QD | TEAE | 17 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 2: Belumosudil 200 mg BID | TEAE | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 3: Belumosudil 400 mg QD | TEAE | 20 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 1: Belumosudil 200 mg QD | TESAE | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 2: Belumosudil 200 mg BID | TESAE | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs) | Cohort 3: Belumosudil 400 mg QD | TESAE | 13 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 1: Belumosudil 200 mg QD | CR | 0 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 2: Belumosudil 200 mg BID | CR | 0 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 3: Belumosudil 400 mg QD | CR | 0 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 1: Belumosudil 200 mg QD | PR | 11 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 2: Belumosudil 200 mg BID | PR | 11 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 3: Belumosudil 400 mg QD | PR | 12 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 1: Belumosudil 200 mg QD | LOR-U | 2 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 2: Belumosudil 200 mg BID | LOR-U | 3 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 3: Belumosudil 400 mg QD | LOR-U | 4 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 1: Belumosudil 200 mg QD | LOR-M | 2 | Participants | |
| Number of Participants With Best Overall Response (BOR) | Cohort 2: Belumosudil 200 mg BID | LOR-M | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02841995/results